For decades, F2F visits were the main way of having a conversation with HCPs. But increasingly restricted access to HCPs and the digital revolution has changed the scene dramatically. Customers want to have a connected omnichannel experience in their daily lives and HCPs are not the exception. What does this mean for pharma? We can and should continue our conversation across appropriate digital channels.

Approved Email is the #2 most impactful channel, after face to face visits, through which pharma communicates with HCPs, connects with hard-to-reach customers, and extends face-to-face conversations without compromising compliance. More than 49% of pharma companies regularly use Approved Email and 39% plan to do so or run an ongoing pilot.

"Customer engagement is all about having meaningful conversations"

In our latest white-paper we discuss:

• The ways to deliver a more consistent level of engagement with valuable and personalised communication.
• Different types of Approved Email and best design practices, layouts, and writing styles.

• Measuring the effectiveness of your emails – insights and metrics to analyse activity, understand results and trends.
• Benchmarks in pharma – what are the average efficiency numbers in the industry, and how to be sure that campaigns perform well.